Insmed to Host Third Quarter 2017 Financial Results Conference Call on Thursday, November 2, 2017
25 Octobre 2017 - 2:00PM
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical
company focused on the unmet needs of patients with rare diseases,
today announced that it will release its third quarter 2017
financial results on Thursday, November 2, 2017.
Insmed management will host a conference call for investors
beginning at 8:30 a.m. ET on Thursday, November 2,
2017 to discuss the financial results and provide a business
update.
Shareholders and other interested parties may participate in the
conference call by dialing (844) 707-0669 (domestic) or (703)
639-1223 (international) and referencing conference ID number
5699819. The call will also be webcast live on the internet on the
company's website at www.insmed.com.
A replay of the conference call will be accessible approximately
two hours after its completion through November 9,
2017 by dialing (855) 859-2056 (domestic) or (404) 537-3406
(international) and referencing conference ID number 5699819. A
webcast of the call will also be archived for 90 days under the
Investor Relations section of the company's website
at www.insmed.com.
About Insmed
Insmed Incorporated is a global biopharmaceutical company
focused on the unmet needs of patients with rare diseases. The
Company’s lead product candidate is ALIS for adult patients with
treatment refractory NTM lung disease caused by MAC, which is a
rare and often chronic infection that is capable of causing
irreversible lung damage and can be fatal. Insmed has
released top-line results from the phase 3 CONVERT study indicating
the trial met the primary endpoint of culture conversion. The
Company is not aware of any approved inhaled therapies specifically
indicated for refractory NTM lung disease caused by MAC in North
America, Japan or Europe. Insmed's earlier-stage clinical
pipeline includes INS1007, a novel oral reversible inhibitor of
dipeptidyl peptidase 1 with therapeutic potential in non-cystic
fibrosis bronchiectasis, and INS1009, an inhaled nanoparticle
formulation of a treprostinil prodrug that may offer a
differentiated product profile for rare pulmonary disorders,
including pulmonary arterial hypertension. For more
information, visit www.insmed.com.
Forward-looking Statements
This press release contains forward looking statements.
"Forward-looking statements," as that term is defined in the
Private Securities Litigation Reform Act of 1995, are statements
that are not historical facts and involve a number of risks and
uncertainties. Words herein such as "may," "will," "should,"
"could," "would," "expects," "plans," "anticipates," "believes,"
"estimates," "projects," "predicts," "intends," "potential,"
"continues," and similar expressions (as well as other words or
expressions referencing future events, conditions or circumstances)
may identify forward-looking statements.
The forward-looking statements in this press release are based
upon the Company’s current expectations and beliefs, and involve
known and unknown risks, uncertainties and other factors, which may
cause the Company’s actual results, performance and achievements
and the timing of certain events to differ materially from the
results, performance, achievements or timing discussed, projected,
anticipated or indicated in any forward-looking statements. Such
factors include, among others: risks that the full six-month data
from the CONVERT study or subsequent data from the remainder of the
study’s treatment and off-treatment phases will not be consistent
with the top-line six-month results of the study; uncertainties in
the research and development of our existing product candidates,
including due to delays in data readouts, such as the full data
from the CONVERT study, patient enrollment and retention or failure
of our preclinical studies or clinical trials to satisfy
pre-established endpoints, including secondary endpoints in the
CONVERT study and endpoints in the INS-312 study; lack of safety
and efficacy of our product candidates; failure to develop, or to
license for development, additional product candidates, including a
failure to attract experienced third-party collaborators; failure
to obtain, or delays in obtaining, regulatory approval from the
United States Food and Drug Administration, Japan’s Ministry of
Health, Labour and Welfare, the European Medicines Agency, and
other regulatory authorities for our product candidates or their
delivery devices, including due to insufficient clinical data or
selection of endpoints that are not satisfactory to regulators,
complexity in the review process for combination products or
inadequate or delayed data from a human factors study required for
U.S. regulatory approval; lack of experience in conducting and
managing preclinical development activities and clinical trials
necessary for regulatory approval, including the regulatory filing
and review process; failure of third parties on which we are
dependent to conduct our clinical trials, to manufacture sufficient
quantities of our product candidates for clinical or commercial
needs, or to comply with our agreements or laws and regulations
that impact our business; failure to comply with license agreements
that are critical for our product development, including our
license agreements with PARI Pharma GmbH and AstraZeneca AB;
inaccuracies in our estimate of the size of the potential markets
for our product candidates; failure to maintain regulatory approval
for our product candidates, if received, due to a failure to
satisfy post-approval regulatory requirements, such as the
submission of sufficient data from confirmatory clinical trials;
uncertainties in the rate and degree of market acceptance of
product candidates, if approved; uncertainties in the timing, scope
and rate of reimbursement for our product candidates; competitive
developments affecting our product candidates; inaccurate estimates
regarding our future capital requirements, including those
necessary to fund our ongoing clinical development, regulatory and
commercialization efforts as well as milestone payments or
royalties owed to third parties; inability to repay our existing
indebtedness or to obtain additional financing when needed; failure
to obtain, protect and enforce our patents and other intellectual
property; inability to create an effective direct sales and
marketing infrastructure or to partner with third parties that
offer such an infrastructure for distribution of our product
candidates, if approved; the cost and potential reputational damage
resulting from litigation to which we are a party, including,
without limitation, the class action lawsuit pending against us;
failure to comply with the laws and regulations that impact our
business; loss of key personnel; and changes in laws and
regulations applicable to our business, including those related to
pricing and reimbursement of our product
candidates.
For additional information about the risks and uncertainties
that may affect our business, please see the factors discussed in
Item 1A, "Risk Factors," in the Company’s Annual Report on Form
10-K for the year ended December 31, 2016.
The Company cautions readers not to place undue reliance on any
such forward-looking statements, which speak only as of the date of
this press release. The Company disclaims any obligation, except as
specifically required by law and the rules of the Securities and
Exchange Commission, to publicly update or revise any such
statements to reflect any change in expectations or in events,
conditions or circumstances on which any such statements may be
based, or that may affect the likelihood that actual results will
differ from those set forth in the forward-looking statements.
Investor Contact:
Blaine Davis Vice President, Head of Investor Relations Insmed
Incorporated (908) 947-2841 blaine.davis@insmed.com
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024